Didrovaltrate

Synonyms: Didrovaltratum
Didrovaltrate (Didrovaltratum) 是一种 L-型钙通道 (L-type calcium channel) 阻滞剂、ROS 清除剂、自噬 (autophagy) 增强剂和脂质蓄积抑制剂,它以浓度依赖的方式阻断 L-型钙电流,使电流-电压曲线上移,调控稳态失活动力学,并抑制糖皮质激素受体的核转位,同时可降低 ROS 水平,下调肌肉萎缩相关基因的表达,通过脂噬增强自噬,并减少 Oleic acid 诱导的脂质蓄积,对癌细胞具有细胞毒性活性,可用于骨骼肌萎缩、非酒精性脂肪性肝病、乳腺癌、肺癌、胃癌和前列腺癌的相关研究。
产品编号: MS-Z35151 纯度: 92.0% CAS No.: 18296-45-2 分子式: C22H32O8 分子量: 424.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Didrovaltrate (Didrovaltratum) 是一种 L-型钙通道 (L-type calcium channel) 阻滞剂、ROS 清除剂、自噬 (autophagy) 增强剂和脂质蓄积抑制剂,它以浓度依赖的方式阻断 L-型钙电流,使电流-电压曲线上移,调控稳态失活动力学,并抑制糖皮质激素受体的核转位,同时可降低 ROS 水平,下调肌肉萎缩相关基因的表达,通过脂噬增强自噬,并减少 Oleic acid 诱导的脂质蓄积,对癌细胞具有细胞毒性活性,可用于骨骼肌萎缩、非酒精性脂肪性肝病、乳腺癌、肺癌、胃癌和前列腺癌的相关研究。

生物实验数据

生物活性 Didrovaltrate (Didrovaltratum) is an L-type calcium channel blocker, ROS scavenger, autophagy enhancer, and lipid accumulation inhibitor that blocks L-type calcium currents in a concentration-dependent manner, shifts the current-voltage curve upward, modulates steady-state inactivation kinetics, and inhibits nuclear translocation of the glucocorticoid receptor; it also reduces ROS levels, downregulates the expression of muscle atrophy-related genes, enhances autophagy via lipophagy, and decreases Oleic acid-induced lipid accumulation, exhibits cytotoxic activity against cancer cells, and can be used in research related to skeletal muscle atrophy, non-alcoholic fatty liver disease, breast cancer, lung cancer, gastric cancer, and prostate cancer.
体外研究
(In Vitro)

Didrovaltrate (30-100 μg/L) 降低 L 型钙电流峰值 (最大 L 型钙电流),分别将其从 6.01 pA/pF 降至 3.45 pA/pF、2.16 pA/pF,抑制率依次为 42.6%、64.1%。
Didrovaltrate (2.5-5 μM; 24 h) 可显著下调 Dexamethasone (DEX) (MS-E10819) 诱导的萎缩 C2C12 肌管中肌肉萎缩标记基因 Atrogin-1、Murf1 和 Mstn 的表达,恢复融合指数与肌管直径,逆转 C2C12 肌管萎缩,降低 ROS 生成,抑制糖皮质激素受体及 FOXO3a 的核转位。
Didrovaltrate (2.5-25 μM; 24 h) 可在 10 μM 及更高浓度下降低 Huh7 肝细胞的活力。
Didrovaltrate (10 μM; 24 h) 以 Atg5 依赖的方式降低 Oleic acid (MS-M89265) 诱导的 Huh7 肝细胞脂质蓄积。
Didrovaltrate (10 μM; 0-24 h) 可增强 Huh7 肝细胞的自噬流,增加细胞中 LC3 斑点的形成。
Didrovaltrate (1-100 μM; 48 h) 可强效抑制 MCF7 人乳腺癌腺癌细胞的活力,其 IC50 为 3.9 μM;经 48 h 处理后,该化合物对 A549、HGC27、PC3 和 HUVEC 细胞系表现出中度至弱的细胞毒活性。

Real Time qPCR

Cell Line: DEX-induced atrophic C2C12 myotubes
Concentration: 2.5, 5 μM
Incubation Time: 24 h (co-incubated with 5 μM DEX)
Result: Significantly downregulated the DEX-induced upregulation of Atrogin-1, Murf1, and Mstn mRNA expression.
Reduced Atrogin-1 expression to ~1.3-fold and ~1.4-fold of the untreated control (from a DEX-induced ~2.2-fold).
Reduced Murf1 expression to ~0.7-fold and ~0.6-fold of the untreated control (from a DEX-induced ~1.9-fold).
Reduced Mstn expression to ~1-fold and ~0.5-fold of the untreated control (from a DEX-induced ~4.5-fold).

Immunofluorescence

Cell Line: DEX-induced atrophic C2C12 myotubes
Concentration: 2.5, 5 μM
Incubation Time: 24 h (co-incubated with 5 μM DEX)
Result: Restored the fusion index from DEX-induced ~42% of the untreated control to ~55% and ~56% respectively.
Restored mean myotube diameter from DEX-induced ~10 μm (from untreated control ~12 μm) to ~11 μm and ~12 μm respectively.
Shifted the myotube diameter distribution away from small diameters (<10 μm) toward larger diameters (>14 μm), reversing the DEX-induced shift toward smaller myotubes.

Western Blot Analysis

Cell Line: DEX-induced atrophic C2C12 myotubes
Concentration: 2.5, 5 μM
Incubation Time: 24 h (co-incubated with 5 μM DEX)
Result: Reduced DEX-induced nuclear GR levels from ~2.81-fold of the untreated control to ~1.98-fold and ~1.81-fold of the untreated control respectively.
Reduced DEX-induced nuclear FOXO3a levels from ~3.75-fold of the untreated control to ~1.74-fold and ~1.53-fold of the untreated control respectively, effectively inhibiting DEX-induced nuclear translocation of both proteins.

Cell Viability Assay

Cell Line: Huh7 hepatocytes
Concentration: 2.5, 5, 10, 25 μM
Incubation Time: 24 h
Result: Reduced cell viability to ~75% of control at 10 μM.
Reduced cell viability to ~38% of control at 25 μM.
Caused no significant changes in cell viability at 2.5 and 5 μM.

Western Blot Analysis

Cell Line: Huh7 hepatocytes
Concentration: 10 μM; 10 μM (with 25 nM BafA1 for final 1 h)
Incubation Time: 0-24 h; 24 h (with 1 h BafA1 treatment)
Result: Increased LC3-II levels relative to LC3-I over time, with the highest ratio (1.5) observed at 24 hours.
Further increased LC3-II levels (ratio of 1.7) compared to BafA1 alone in the presence of BafA1.

Immunofluorescence

Cell Line: Huh7 hepatocytes
Concentration: 10 μM
Incubation Time: 24 h
Result: Increased the formation of LC3 puncta compared to vehicle-treated cells.

Cell Cytotoxicity Assay

Cell Line: human lung adenocarcinoma (A549), human breast adenocarcinoma (MCF7), human gastric carcinoma (HGC27), human prostate adenocarcinoma (PC3), human umbilical vein endothelial (HUVEC)
Concentration: 1-100 μM
Incubation Time: 48 h
Result: Inhibited cell viability of A549 cell line with an IC50 of 26.7 μM.
Inhibited cell viability of MCF7 cell line with an IC50 of 3.9 μM.
Inhibited cell viability of HGC27 cell line with an IC50 of 12.6 μM.
Inhibited cell viability of PC3 cell line with an IC50 of 69.3 μM.
Inhibited cell viability of HUVEC cell line with an IC50 of 14.8 μM.
Exhibited the most potent activity against the MCF7 breast cancer cell line.
性状 固体
颜色 White to off-white

化学信息

分子量 424.48
分子式 C22H32O8
CAS No. 18296-45-2
别名 Didrovaltratum

储存&溶解度

储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础